ArticleExperimental and therapeutic medicine2019
LncRNA ZFAS1 serves as a prognostic biomarker to predict the survival of patients with ovarian cancer.
Article in Experimental and therapeutic medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.
- Identification of lncRNAs Deregulated in Epithelial Ovarian Cancer Based on a Gene Expression Profiling Meta-Analysis.International journal of molecular sciences · 2023Pooled it
- LncRNA ZFAS1 in hepatocellular carcinoma: A systematic review of molecular mechanisms and clinical translation.Non-coding RNA research · 2026Review
- The Expression Analysis of Long Non-coding RNAs Related to Wnt/β-Catenin Signaling in Pancreatic Cancer Patients.Biochemical genetics · 2025Article
- Single cell RNA-seq analysis identifies a noncoding RNA mediating resistance to sorafenib treatment in HCC.Molecular cancer · 2022Article
- lncRNA ZFAS1 promotes the ox-LDL induced proliferation, invasion and migration of vascular smooth muscle cells.Experimental and therapeutic medicine · 2021Article
- LncRNA FGD5-AS1 promotes the malignant phenotypes of ovarian cancer cells via targeting miR-142-5p.Apoptosis : an international journal on programmed cell death · 2021Article
- Noncoding RNA (ncRNA) Profile Association with Patient Outcome in Epithelial Ovarian Cancer Cases.Reproductive sciences (Thousand Oaks, Calif.) · 2021Article
- The Challenges and Opportunities of LncRNAs in Ovarian Cancer Research and Clinical Use.Cancers · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer (OC) is one of the most fatal types of gynecological malignancy. Certain long non-coding RNAs (lncRNA) have been reported to have crucial roles in cancer progression. Zinc finger nuclear transcription factor, X-box binding 1-type containing 1 antisense RNA 1 (ZFAS1) is a novel regulator lncRNA in various cancer types. The expression pattern of most lncRNAs, including ZFAS1, in OC remains to be determined. In the present study, it was demonstrated that ZFAS1 was overexpressed in OC vs. normal cell lines. However, ZFAS1 was downregulated in OC compared with normal samples in the GEPIA dataset. Furthermore, OC samples of higher stages (stage III/IV) had higher levels of ZFAS1 compared with those in early-stage OC (stage I/II) samples. Of note, higher ZFAS1 expression was associated with shorter overall survival time and disease-free survival time of OC patients. Protein-protein interaction networks of proteins co-expressed with ZFAS1 in OC were constructed. Furthermore, Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analysis of genes co-expressed with ZFAS1 indicated that ZFAS1 is associated with translation, mRNA splicing, cell-cell adhesion, DNA repair, protein sumoylation, positive regulation of GTPase activity and DNA replication. The present study may provide novel clues to validate ZFAS1 as a biomarker in OC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.